Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Kelly Allott^{1

2}, Walid Yassin³, Luis Alameda^{4

5}, Tashrif Billah⁶, Owen Borders⁶, Kate Buccilli^{7

8}, Ricardo E Carrión^{9

10}, Rolando I Castillo-Passi^{11

12}, Kang Ik K Cho⁶, Kota Chin⁶, Michael J Coleman⁶, Beau-Luke Colton^{7

8}, Sebastián Corral^{13

14}, Dominic Dwyer^{7

8}, Kristina Ballestad Gundersen^{15

16}, Ruben C Gur¹⁷, Gil D Hoftman¹⁸, Grace R Jacobs⁶, Sinead Kelly⁶, Kathryn E Lewandowski^{19

20}, Patricia J Marcy¹⁸, Priya Matneja¹⁸, Danielle McLaughlin¹⁸, Angela R Nunez^{21

22}, Setari Parsa³, Nora Penzel²³, Susan Ray¹⁸, Jenna M Reinen^{24

25}, Kosha Ruparel¹⁷, Michael S Sand²⁶, Gennarina Santorelli³, Johanna Seitz-Holland^{6

23}, Jessica Spark^{7

8}, Zailyn Tamayo²¹, Andrew Thompson^{7

8

27}, Sophie Tod^{7

8}, Cassandra M J Wannan^{7

8}, Alana Wickham⁶, Stephen J Wood^{7

8

28}, Eirini Zoupou¹⁷, Jean Addington²⁹, Alan Anticevic^{21

30}, Celso Arango³¹, Nicholas J K Breitborde³², Matthew R Broome^{33

34}, Kristin S Cadenhead³⁵, Monica E Calkins¹⁷, Eric Yu Hai Chen^{36

37}, Jimmy Choi³⁸, Philippe Conus⁴, Cheryl M Corcoran³⁹, Barbara A Cornblatt^{9

10}, Lauren M Ellman⁴⁰, Paolo Fusar-Poli^{41

42}, Pablo A Gaspar^{10

11}, Carla Gerber^{43

44}, Louise Birkedal Glenthøj^{15

16}, Leslie E Horton⁴⁵, Christy Lai Ming Hui³⁶, Joseph Kambeitz⁴⁶, Lana Kambeitz-Ilankovic^{46

47}, Matcheri Keshavan³, Sung-Wan Kim^{48

49}, Nikolaos Koutsouleris^{41

47}, Jun Soo Kwon^{50

51}, Kerstin Langbein⁵², Daniel Mamah⁵³, Covadonga M Diaz-Caneja³¹, Daniel H Mathalon^{54

55}, Vijay A Mittal⁵⁶, Merete Nordentoft^{57

58}, Godfrey D Pearlson^{59

60}, Diana O Perkins⁶¹, Jesus Perez^{62

63}, Albert R Powers 3rd^{22

60}, Jack Rogers^{33

64}, Fred W Sabb⁴³, Jason Schiffman⁶⁵, Jai L Shah^{66

67}, Steven M Silverstein⁶⁸, Stefan Smesny⁵², Gregory P Strauss⁶⁹, Judy L Thompson⁶⁸, Rachel Upthegrove^{33

37}, Swapna K Verma^{70

71}, Jijun Wang⁷², Daniel H Wolf¹⁷, Ofer Pasternak^{6

23}, Sylvain Bouix⁷³, Patrick D McGorry^{7

8}, John M Kane^{9

10}, Rene S Kahn³⁹, Carrie E Bearden^{74

75}, Martha E Shenton^{76

77}, Scott W Woods^{22

60}, Barnaby Nelson^{7

8}; Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ); William S Stone³

Affiliations

¹ Orygen, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
² Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
³ Department of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA, USA.
⁴ General Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁵ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
⁶ Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Orygen, Parkville, VIC, Australia.
⁸ Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.
⁹ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY, USA.
¹⁰ Institute of Behavioral Science, Feinstein Institute for Medical Research, Manhasset, NY, USA.
¹¹ Department of Psychiatry, IMHAY, University of Chile, Santiago, Chile.
¹² Department of Neurology and Psychiatry, Clínica Alemana-Universidad del Desarrollo, Santiago, RM, Chile.
¹³ Department of Psychiatry, University of Chile, Santiago, Chile.
¹⁴ Departamento de Psicologia, Universidad de La Serena, La Serena, Chile.
¹⁵ VIRTU Research Group, Copenhagen Research Centre for Mental Health, Mental Health Copenhagen, University of Copenhagen, Copenhagen, Denmark.
¹⁶ Department of Psychology, University of Copenhagen, Copenhagen, Denmark.
¹⁷ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁸ Northwell Health, Glen Oaks, NY, USA.
¹⁹ Psychotic Disorders Division, McLean Hospital, Belmont, MA, USA.
²⁰ Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
²¹ Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
²² Connecticut Mental Health Center, New Haven, CT, USA.
²³ Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
²⁴ IBM Research, Armonk, NY, USA.
²⁵ T.J. Watson Research Laboratory, Yorktown Heights, NY, USA.
²⁶ S2 Consulting LLC, Monroe, CT, USA.
²⁷ Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, USA.
²⁸ School of Psychology, University of Birmingham, Edgbaston, UK.
²⁹ Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
³⁰ Yale University Department of Psychiatry, New Haven, CT, USA.
³¹ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
³² Department of Psychiatry and Behavioral Health, Ohio State University, Columbus, OH, USA.
³³ Institute for Mental Health, School of Psychology, University of Birmingham, Birmingham, UK.
³⁴ Early Intervention for Psychosis Services, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
³⁵ University of California, San Diego, CA, USA.
³⁶ Department of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
³⁷ Department of Psychiatry, University of Oxford, Oxford, UK.
³⁸ Olin Neuropsychiatry Research Center, Hartford Health Care Behavioral Health Network, Hartford, CT, USA.
³⁹ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴⁰ Department of Psychology & Neuroscience, Temple University, Philadelphia, PA, USA.
⁴¹ Department of Psychosis Studies, King's College London, London, UK.
⁴² Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
⁴³ Prevention Science Institute, University of Oregon, Eugene, OR, USA.
⁴⁴ Oregon Research Institute, Springfield, OR, USA.
⁴⁵ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
⁴⁶ University of Cologne, Faculty of Medicine and University HospitalCologne, Cologne, Germany.
⁴⁷ Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University Munich, Munich, Germany.
⁴⁸ Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea.
⁴⁹ Mindlink, Gwangju Bukgu Mental Health Center, Gwangju, Republic of Korea.
⁵⁰ Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea.
⁵¹ Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea.
⁵² Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.
⁵³ Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
⁵⁴ Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
⁵⁵ Mental Health Service 116D, Veterans Affairs San Francisco Health Care System, San Francisco, CA, USA.
⁵⁶ Department of Psychology, Northwestern University, Chicago, IL, USA.
⁵⁷ Copenhagen Research Centre for Mental Health, Mental Health Copenhagen, University of Copenhagen, Copenhagen, Denmark.
⁵⁸ Department of Clinical Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
⁵⁹ Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA.
⁶⁰ Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
⁶¹ Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA.
⁶² CAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
⁶³ Institute of Biomedical Research (IBSAL), Department of Medicine, Universidad de Salamanca, Salamanca, Spain.
⁶⁴ Centre for Human Brain Health, University of Birmingham, Birmingham, UK.
⁶⁵ Department of Psychological Science, University of California, Irvine, CA, USA.
⁶⁶ PEPP-Montreal, Douglas Research Centre, Montreal, QC, Canada.
⁶⁷ Department of Psychiatry, McGill University, Montreal, QC, Canada.
⁶⁸ Department of Psychiatry, University of Rochester Medical Center, Rochester, NY, USA.
⁶⁹ Department of Psychology, University of Georgia, Athens, GA, USA.
⁷⁰ Institute of Mental Health, Singapore, Singapore.
⁷¹ Duke-NUS Medical School, Singapore, Singapore.
⁷² Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
⁷³ Department of Software Engineering and Information Technology, Ecole de technologie superieure, Montreal, QC, Canada.
⁷⁴ Departments of Psychiatry and Biobehavioral Sciences & Psychology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
⁷⁵ Department of Psychology, University of California, Los Angeles, CA, USA.
⁷⁶ Departments of Psychiatry and Radiology, Brigham and Women's Hospital, and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁷⁷ Massachusetts General Hospital, Boston, MA, USA.

PMID: 40128256
PMCID: PMC11933323
DOI: 10.1038/s41537-025-00578-1

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Kelly Allott et al. Schizophrenia (Heidelb). 2025.

. 2025 Mar 24;11(1):49.

doi: 10.1038/s41537-025-00578-1.

Authors

Affiliations

¹ Orygen, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
² Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia. kelly.allott@orygen.org.au.
³ Department of Psychiatry, Beth Israel Deaconess Medical Center, Massachusetts Mental Health Center and Harvard Medical School, Boston, MA, USA.
⁴ General Psychiatry Service, Treatment and Early Intervention in Psychosis Program (TIPP-Lausanne), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁵ Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College of London, London, UK.
⁶ Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Orygen, Parkville, VIC, Australia.
⁸ Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.
⁹ Department of Psychiatry, Donald and Barbara Zucker School of Medicine, Hempstead, NY, USA.
¹⁰ Institute of Behavioral Science, Feinstein Institute for Medical Research, Manhasset, NY, USA.
¹¹ Department of Psychiatry, IMHAY, University of Chile, Santiago, Chile.
¹² Department of Neurology and Psychiatry, Clínica Alemana-Universidad del Desarrollo, Santiago, RM, Chile.
¹³ Department of Psychiatry, University of Chile, Santiago, Chile.
¹⁴ Departamento de Psicologia, Universidad de La Serena, La Serena, Chile.
¹⁵ VIRTU Research Group, Copenhagen Research Centre for Mental Health, Mental Health Copenhagen, University of Copenhagen, Copenhagen, Denmark.
¹⁶ Department of Psychology, University of Copenhagen, Copenhagen, Denmark.
¹⁷ Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
¹⁸ Northwell Health, Glen Oaks, NY, USA.
¹⁹ Psychotic Disorders Division, McLean Hospital, Belmont, MA, USA.
²⁰ Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
²¹ Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
²² Connecticut Mental Health Center, New Haven, CT, USA.
²³ Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
²⁴ IBM Research, Armonk, NY, USA.
²⁵ T.J. Watson Research Laboratory, Yorktown Heights, NY, USA.
²⁶ S2 Consulting LLC, Monroe, CT, USA.
²⁷ Division of Mental Health and Wellbeing, Warwick Medical School, University of Warwick, Coventry, USA.
²⁸ School of Psychology, University of Birmingham, Edgbaston, UK.
²⁹ Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
³⁰ Yale University Department of Psychiatry, New Haven, CT, USA.
³¹ Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, ISCIII, School of Medicine, Universidad Complutense, Madrid, Spain.
³² Department of Psychiatry and Behavioral Health, Ohio State University, Columbus, OH, USA.
³³ Institute for Mental Health, School of Psychology, University of Birmingham, Birmingham, UK.
³⁴ Early Intervention for Psychosis Services, Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
³⁵ University of California, San Diego, CA, USA.
³⁶ Department of Psychiatry, School of Clinical Medicine, LKF Faculty of Medicine, University of Hong Kong, Hong Kong SAR, China.
³⁷ Department of Psychiatry, University of Oxford, Oxford, UK.
³⁸ Olin Neuropsychiatry Research Center, Hartford Health Care Behavioral Health Network, Hartford, CT, USA.
³⁹ Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
⁴⁰ Department of Psychology & Neuroscience, Temple University, Philadelphia, PA, USA.
⁴¹ Department of Psychosis Studies, King's College London, London, UK.
⁴² Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
⁴³ Prevention Science Institute, University of Oregon, Eugene, OR, USA.
⁴⁴ Oregon Research Institute, Springfield, OR, USA.
⁴⁵ Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
⁴⁶ University of Cologne, Faculty of Medicine and University HospitalCologne, Cologne, Germany.
⁴⁷ Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University Munich, Munich, Germany.
⁴⁸ Department of Psychiatry, Chonnam National University Medical School, Gwangju, Republic of Korea.
⁴⁹ Mindlink, Gwangju Bukgu Mental Health Center, Gwangju, Republic of Korea.
⁵⁰ Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea.
⁵¹ Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea.
⁵² Department of Psychiatry and Psychotherapy, Jena University Hospital, Jena, Germany.
⁵³ Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
⁵⁴ Department of Psychiatry and Behavioral Sciences and Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA.
⁵⁵ Mental Health Service 116D, Veterans Affairs San Francisco Health Care System, San Francisco, CA, USA.
⁵⁶ Department of Psychology, Northwestern University, Chicago, IL, USA.
⁵⁷ Copenhagen Research Centre for Mental Health, Mental Health Copenhagen, University of Copenhagen, Copenhagen, Denmark.
⁵⁸ Department of Clinical Medicine, Copenhagen University Hospital, Copenhagen, Denmark.
⁵⁹ Olin Neuropsychiatry Research Center, Institute of Living, Hartford Hospital, Hartford, CT, USA.
⁶⁰ Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
⁶¹ Department of Psychiatry, University of North Carolina, Chapel Hill, NC, USA.
⁶² CAMEO, Early Intervention in Psychosis Service, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
⁶³ Institute of Biomedical Research (IBSAL), Department of Medicine, Universidad de Salamanca, Salamanca, Spain.
⁶⁴ Centre for Human Brain Health, University of Birmingham, Birmingham, UK.
⁶⁵ Department of Psychological Science, University of California, Irvine, CA, USA.
⁶⁶ PEPP-Montreal, Douglas Research Centre, Montreal, QC, Canada.
⁶⁷ Department of Psychiatry, McGill University, Montreal, QC, Canada.
⁶⁸ Department of Psychiatry, University of Rochester Medical Center, Rochester, NY, USA.
⁶⁹ Department of Psychology, University of Georgia, Athens, GA, USA.
⁷⁰ Institute of Mental Health, Singapore, Singapore.
⁷¹ Duke-NUS Medical School, Singapore, Singapore.
⁷² Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai, China.
⁷³ Department of Software Engineering and Information Technology, Ecole de technologie superieure, Montreal, QC, Canada.
⁷⁴ Departments of Psychiatry and Biobehavioral Sciences & Psychology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA, USA.
⁷⁵ Department of Psychology, University of California, Los Angeles, CA, USA.
⁷⁶ Departments of Psychiatry and Radiology, Brigham and Women's Hospital, and Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁷⁷ Massachusetts General Hospital, Boston, MA, USA.

PMID: 40128256
PMCID: PMC11933323
DOI: 10.1038/s41537-025-00578-1

Abstract

Cognitive impairment occurs at higher rates in individuals at clinical high risk (CHR) for psychosis relative to healthy peers, and it contributes unique variance to multivariate prediction models of transition to psychosis. Such impairment is considered a core biomarker of schizophrenia. Thus, cognition is a key domain measured in the Accelerating Medicines Partnership® program for Schizophrenia (AMP SCZ initiative). The aim of this paper is to describe the rationale, processes, considerations, and final harmonization of the cognitive battery used in AMP SCZ across the two data collection networks. This battery comprises tests of general intellect and specific cognitive domains. We estimate premorbid intelligence at baseline and measure current intelligence at baseline and 2 years. Eight tests from the Penn Computerized Neurocognitive Battery (PennCNB), which measure verbal learning and memory, sensorimotor ability, attention, emotion recognition, working memory, processing speed, verbal memory, visual memory, and motor speed are administered repeatedly at baseline, and four follow-up timepoints over 2 years.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare the following competing interests: K.A. is on the Australian Cognitive Impairment Associated with Schizophrenia Advisory Board for Boehringer Ingelheim and receives honorary funds; D.D. has received honorary funds for one educational seminar for CSL Sequiris; A.A. is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc.; and is a coinventor on the following patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for NeuroBehavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019; E.C. has received speaker fees at non-promotional educational events; P.F.P. has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Proxymm Science, Otsuka, outside the current study; J.K. has received speaking or consulting fees from Janssen, Boehringer Ingelheim, ROVI and Lundbeck; C.D.C. has received grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation and honoraria or travel support from Angelini, Janssen, and Viatris; R.U. has received speaker fees at non promotional educational event: Otsuka: Consultancy for Viatris and Springer HealtCCare. Honorary General Secretary British Association for Psychopharmacology (unpaid); JMK is a consultant to or receives honoraria and/or travel support and/or speakers bureau: Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Meyer-Squibb, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, Teva. Advisory Boards: Alkermes, Boehringer-Ingelheim, Cerevel, Click Therapeutics, Karuna/BMS, Lundbeck, Merck, Newron, Novartis, Otsuka, Sumitomo, Teva, Terran Grant Support: Lundbeck, Janssen, Otsuka, Sunovion Shareholder: Cerevel (public/stock), HealthRhythms (private/stock options), Karuna/BMS (public), LB Pharmaceuticals, Inc. (private/stock options), North Shore Therapeutics (private/stock), Vanguard Research Group (private/40% owner) Receives Royalties: Up to Date; RSK provides consulting to Alkermes, Boehringer-Ingelheim; S.W.W. has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonists. He owns stock in NW PharmaTech; C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda; G.D.H. has been a consultant for Bristol Myers Squibb; P.J.M. has been a consultant for Otsuka and TEVA; and Z.T. has been a consult for Manifest Technologies. All other authors report no competing interests. C.M.C. is an Associate Editor of Schizophrenia.

Figures

**Fig. 1. Comparison between CHR and CC in the AMP SCZ Cognition Battery at baseline.**
a current IQ, b verbal learning, c attention, d emotion recognition, e working memory, f processing speed, g visual memory, h motor speed, i estimated premorbid IQ, j PennCNB composite. WRAT-5 Wide Range Achievement Test, IQ Full Scale Intelligence Quotient, SPLLT Short Penn List Learning Test, SPCPTNL Short Penn Continuous Performance Test, ER40 Penn Emotion Recognition Test, SFNB Short Fractal N-Back Test, DIGSYM Digit-Symbol Test, SVOLT Short Visual Object Learning Test, SCTAP Short Computerized Finger Tapping Test. CHR Clinical High Risk, CC Community Control. Composite is the average of all tests except IQ, SPLLT, and SVOLT. Significance level “***“<0.001, “**“<0.01, “*“<0.05, “NS” > 0.05.

**Fig. 2. Consistency and reliability of the AMP SCZ Cognition Battery between baseline and 8 weeks later for the CHR participants.**
a attention, b emotion recognition, c working memory, d processing speed, e motor speed, f visual memory, g PennCNB composite. SPCPTNL Short Penn Continuous Performance Test, ER40 Penn Emotion Recognition Test, SFNB Short Fractal N-Back Test, DIGSYM Digit-Symbol Test, SVOLT Short Visual Object Learning Test, SCTAP Short Computerized Finger Tapping Test, CHR Clinical High Risk. Composite is the average of all tests except SVOLT. CHR Clinical High Risk. V1 Visit 1 (baseline), V2 Visit 2 (1 month after baseline). Significance level according to ICC, “⊗“<0.001, “⊕“<0.01, “⊖“<0.05, “NS” >0.05. Significance level according to paired comparisons “***“<0.001, “**“<0.01, “*“<0.05, “NS” > 0.05, with blue color indicating increase, and red decrease from baseline.

See this image and copyright information in PMC

References

1. McCutcheon, R. A., Keefe, R. S. E. & McGuire, P. K. Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. Mol. Psychiatry28, 1902–1918 (2023). - PMC - PubMed
1. Catalan, A. et al. Neurocognitive functioning in individuals at clinical high risk for psychosis: a systematic review and meta-analysis. JAMA Psychiatry78, 859–867 (2021). - PMC - PubMed
1. Stainton, A. et al. Prevalence of cognitive impairments and strengths in the early course of psychosis and depression. Psychol. Med.53, 5945–5957 (2023). - PMC - PubMed
1. Bonivento, C. et al. Neurocognitive skills and vulnerability for psychosis in depression and across the psychotic spectrum: findings from the PRONIA Consortium. Br. J. Psychiatry223, 485–492 (2023). - PubMed
1. Nuechterlein, K. H. et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry165, 203–213 (2008). - PubMed

Grants and funding

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Affiliations

Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Grants and funding

LinkOut - more resources

Full Text Sources